New trial
Phase 1/2 study of GSK5458514, a PSMA-targeting T cell engager for prostate cancer.
- Trial ID
- NCT06990880 on ClinicalTrials.gov
- Cancer type
- Prostate Cancer
- Stage of research
- First-in-human
- Location
- 2 Locations
- Published in
- New in Oncology - July 25, 2025
This study investigates the safety, tolerability, and dosing of GSK5458514 monotherapy in adults with metastatic castration-resistant prostate cancer across a two-part open-label design featuring dose escalation and expansion. It is a first-in-human evaluation of this novel immunotherapy approach sponsored by GlaxoSmithKline.
More in prostate cancer
-
Trial result · Oct 22, 2026 · NCT03732820
Olaparib (PARP inhibitor) + Abiraterone (CYP17 AR-pathway inhibitor) Extends rPFS in Non‑BRCA mCRPC (PROpel) -
New trial · Oct 15, 2026 · NCT07813637
Phase 1 JANX013 PSMA×CD28 costimulation combines with JANX007 PSMA×CD3 T-cell engagement -
New trial · Oct 15, 2026 · NCT07832292
Phase 2 JNJ-101556143 uses an AR-BRD4 induced-proximity mechanism in resistant prostate cancer -
New trial · Oct 8, 2026 · NCT07824349
Phase 1a/1b JUR-003 KLK2×CD3 bispecific T‑cell engager in metastatic prostate cancer -
New trial · Oct 1, 2026 · NCT07803653
Phase 1 FH-STEAP1 IL-18 CAR T tests STEAP1-targeted CAR-T armored with IL-18